Bristol-Myers Squibb: Glioblastoma trials

The registry lists 16 Glioblastoma studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 12Phase 2 5Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
• An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02667587Phase 3Results posted
• An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02617589Phase 3Results posted
• Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and BevacizumabCompletedNCT02330562Phase 1/2Results posted
• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)TerminatedNCT00948389Phase 1/2Results posted
• A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed GlioblastomaTerminatedNCT04324840Phase 1
• CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and GlioblastomaTerminatedNCT04047303Phase 1
• Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain CancerCompletedNCT02903069Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma MultiformeStatus unknownNCT00768911Phase 1
• CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With IrinotecanStatus unknownNCT00562419Phase 2
• Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade GliomasCompletedNCT00074646Phase 1